Polaryx Therapeutics (PLYX) Total Liabilities (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Total Liabilities for 3 consecutive years, with $873000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 126.89% year-over-year to $873000.0 in Q2 2026; TTM through Jun 2026 was $873000.0, a 126.89% increase from a year earlier, with the FY2025 full-year figure at $605000.0, up 109.34% from the prior year.
• Total Liabilities was $873000.0 for Q2 2026 at Polaryx Therapeutics, down from $1.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $1.0 million in Q1 2026 and troughed at -$4.3 million in Q1 2025.
• A 3-year average of -$786500.0 and a median of $447000.0 in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 109.34% in 2025 and jumped 126.89% in 2026, its largest moves.
• Over 3 years, Total Liabilities stood at $289000.0 in 2024, then soared by 109.34% to $605000.0 in 2025, then surged by 44.3% to $873000.0 in 2026.
• The last three Total Liabilities figures came in at $873000.0 (Q2 2026), $1.0 million (Q1 2026), and $605000.0 (Q4 2025), per Business Quant data.